New ibrutinib (IMBRUVICA(R)) Data to be Presented at American Association for Cancer Research (AACR)...
New ibrutinib (IMBRUVICA(R)) Data to be Presented at American Association for Cancer Research (AACR) Meeting: Pre-clinical data to be presented in solid tumor and blood cancer models
About this item
Full title
Publisher
New York: PR Newswire Association LLC
Journal title
Language
English
Formats
Publication information
Publisher
New York: PR Newswire Association LLC
Subjects
More information
Scope and Contents
Contents
Monday, April 20, 2015 at 1:00 - 5:00 p.m. ET in Section 29Lead Author: Silvia Xargay-Torrent, IDIBAPS, Barcelona, Spain About IMBRUVICAIMBRUVICA (ibrutinib) is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK).1 BTK is a key signaling molecule in the B-cell receptor signaling complex that play...
Alternative Titles
Full title
New ibrutinib (IMBRUVICA(R)) Data to be Presented at American Association for Cancer Research (AACR) Meeting: Pre-clinical data to be presented in solid tumor and blood cancer models
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_1664427621
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_1664427621
